Bristol-Myers Squibb Company (BVL:BMYUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 437.23B +39.2% |
| Revenue (ttm) | 167.96B +3.1% |
| Net Income | 31.70B +83.8% |
| EPS | 15.51 +82.7% |
| Shares Out | n/a |
| PE Ratio | 13.79 |
| Forward PE | 9.54 |
| Dividend | 8.81 (4.01%) |
| Ex-Dividend Date | Oct 2, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 63.88 |
| Day's Range | n/a |
| 52-Week Range | 43.50 - 67.28 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About BVL:BMYUS
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
News
Bristol Myers’ Camzyos approved by FDA in cardiomyopathy
Bristol Myers (BMY) announced that the FDA approved Camzyos – mavacamten – for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, or oHCM, to improve functional capacity and symptom...
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. FDA Approves Expanded Indication for BMS's CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients.
FDA approves Bristol Myers’ Camzyos capsules for children with oHCM
The U.S. Food and Drug Administration approved Bristol Myers (BMY)’ Camzyos capsules as the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy to improve functional ...
Bristol Myers reports results from prespecified analysis of EXCALIBER-RRMM trial
Bristol Myers (BMY) Squibb announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial evaluating Zenbexus in combination with daratumumab a...
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #IMS26--BMS Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial.
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026.
Bristol Myers’ Sotyktu shows two-year efficacy in in psoriatic arthritis
Bristol Myers (BMY) announced positive results through two years of treatment from the Phase 3 POETYK PsA-2 study, including its open-label extension, showing durable efficacy and a consistent safety ...
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CCRWest2026--Bristol Myers Squibb Presents Sotyktu Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years.
Bristol Myers price target raised to $82 from $75 at Piper Sandler
Piper Sandler raised the firm’s price target on Bristol Myers (BMY) to $82 from $75 and keeps an Overweight rating on the shares. The firm continues to believe that the…
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers price target raised to $65 from $60 at HSBC
HSBC raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare group…
Bristol Myers' blood cancer cell therapy meets main goal in mid-stage trial
Bristol Myers Squibb said on Tuesday its experimental cell therapy for a type of blood cancer had met the main goal of a mid-stage trial.
Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial
Bristol Myers (BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL trial of arlocabtagene autoleucel in adult patients with quadruple-class exposed relapsed and refractory m...
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial.
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Eikon Therapeutics appoints Ching-Pin Chang as chief scientific officer
Eikon Therapeutics (EIKN) announced the appointment of Ching-Pin Chang as executive VP and chief scientific officer. Chang joins Eikon from Bristol Myers (BMY), where he most recently served as VP,…
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
Technical indicators have turned bullish for the three stocks.
Bristol Myers presents results for EXPLORER-LTE cohort of MAVA-LTE study
Bristol Myers (BMY) Squibb presented results from the EXPLORER-LTE cohort of the MAVA-LTE study in a late-breaker presentation at the European Society of Cardiology, ESC, Congress 2026 in Munich, Germ...
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its personalized blood cancer therapy, a company spokesperson told Reuters on Tuesday...
Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery.
The Key to Pharma M&A: Never Shopping Hungry
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS.
US FDA approves Bristol Myers' blood cancer treatment
The U.S. FDA on Thursday approved Bristol Myers Squibb's combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the he...